Table 4. Clinical features of participants with and without coenzyme Q10 exposure.
CoQ10 exposure | SCA1 | SCA2 | SCA3 | SCA6 | ||||
---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||
Yes | No | Yes | No | Yes | No | Yes | No | |
Sample size, n | 14 | 39 | 9 | 60 | 31 | 98 | 20 | 48 |
Mean age, years | 50.0 ± 9.4 | 50.4 ± 14.2 | 51.7 ± 11.6 | 50.8 ± 13.8 | 52.3 ± 11.2 | 51.1 ± 12.6 | 65.9 ± 9.7 | 65.3 ± 11.3 |
Male, % | 28.6 | 51.3 | 33.3 | 43.3 | 58.1 | 44.9 | 40 | 45.8 |
White race, % | 100 | 87.2 | 77.8 | 73.3 | 71 | 49 | 95 | 89.6 |
Age at onset, years | 40.5 ± 12.1 | 40.1 ± 11.7 | 41.3 ± 13.1 | 35.6 ± 11.7 | 41.7 ± 10.9 | 38 ± 12.1 | 52.9 ± 10.6 | 52.1 ± 10.5 |
Disease duration, years | 8.1 ± 9.0 | 9.1 ± 6.2 | 9.1 ± 4.7 | 14.3 ± 8.6 | 9.3 ± 6.5 | 12.2 ± 8.1 | 11.6 ± 11.5 | 11.7 ± 10.1 |
CAG repeats | 45.9 ± 2.8 | 46.2 ± 4.9 | 38.8 ± 2.2 | 39.7 ± 3.8 | 71.2 ± 3.5 | 70.6 ± 4.2 | 22.4 ± 0.7 | 22.4 ± 1.0 |
Baseline SARA | 9.2 ± 5.8 | 16.2 ± 8.2 | 13.7 ± 5.7 | 17.6 ± 7.5 | 12.5 ± 8.3 | 16.0 ± 9.0 | 13.7 ± 8.5 | 14.2 ± 7.0 |
Concomitant drugs, n | 5.4 ± 4.6 | 3.9 ± 3.2 | 4.1 ± 2.7 | 4.3 ± 3.6 | 6.1 ± 3.5 | 5.2 ± 4.2 | 6.8 ± 4.0 | 4.9 ± 4.4 |
Mean ± standard deviation is reported.